PE20061041A1 - Formulaciones y regimen de dosificacion para moduladores alfa de ppar - Google Patents
Formulaciones y regimen de dosificacion para moduladores alfa de pparInfo
- Publication number
- PE20061041A1 PE20061041A1 PE2006000107A PE2006000107A PE20061041A1 PE 20061041 A1 PE20061041 A1 PE 20061041A1 PE 2006000107 A PE2006000107 A PE 2006000107A PE 2006000107 A PE2006000107 A PE 2006000107A PE 20061041 A1 PE20061041 A1 PE 20061041A1
- Authority
- PE
- Peru
- Prior art keywords
- formulations
- dosing regime
- ppar modulators
- methyl
- alpha
- Prior art date
Links
- 102000003728 Peroxisome Proliferator-Activated Receptors Human genes 0.000 title abstract 2
- 108090000029 Peroxisome Proliferator-Activated Receptors Proteins 0.000 title abstract 2
- 239000000203 mixture Substances 0.000 title 1
- -1 4-METHYLPHENYL Chemical class 0.000 abstract 1
- 208000000103 Anorexia Nervosa Diseases 0.000 abstract 1
- 208000032928 Dyslipidaemia Diseases 0.000 abstract 1
- 208000017170 Lipid metabolism disease Diseases 0.000 abstract 1
- 208000008589 Obesity Diseases 0.000 abstract 1
- OCBFFGCSTGGPSQ-UHFFFAOYSA-N [CH2]CC Chemical compound [CH2]CC OCBFFGCSTGGPSQ-UHFFFAOYSA-N 0.000 abstract 1
- 239000000556 agonist Substances 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 abstract 1
- 239000002552 dosage form Substances 0.000 abstract 1
- WCYWZMWISLQXQU-UHFFFAOYSA-N methyl Chemical class [CH3] WCYWZMWISLQXQU-UHFFFAOYSA-N 0.000 abstract 1
- DUWWHGPELOTTOE-UHFFFAOYSA-N n-(5-chloro-2,4-dimethoxyphenyl)-3-oxobutanamide Chemical compound COC1=CC(OC)=C(NC(=O)CC(C)=O)C=C1Cl DUWWHGPELOTTOE-UHFFFAOYSA-N 0.000 abstract 1
- 235000020824 obesity Nutrition 0.000 abstract 1
- KHUXNRRPPZOJPT-UHFFFAOYSA-N phenoxy radical Chemical compound O=C1C=C[CH]C=C1 KHUXNRRPPZOJPT-UHFFFAOYSA-N 0.000 abstract 1
- 235000019260 propionic acid Nutrition 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 239000007787 solid Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4196—1,2,4-Triazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Landscapes
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Diabetes (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Cardiology (AREA)
- Neurosurgery (AREA)
- Heart & Thoracic Surgery (AREA)
- Epidemiology (AREA)
- Endocrinology (AREA)
- Urology & Nephrology (AREA)
- Emergency Medicine (AREA)
- Child & Adolescent Psychology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Nutrition Science (AREA)
- Vascular Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
REFERIDA A UNA FORMA DE DOSIFICACION UNITARIA ORAL SOLIDA QUE COMPRENDE ACIDO PROPANOICO, 2-[4-[3-[2,5-DIHIDRO-1-[(4-METILFENIL)METIL]-5-OXO-1H-1,2,4-TRIAZOL-3-IL]PROPIL]FENOXI]-2-METIL O UNA SAL FARMACEUTICA DEL MISMO, DONDE DICHOS COMPUESTOS ACTIVOS SON AGONISTAS ALFA DE PPAR. DICHA FORMA DE DOSIS UNITARIA SE ENCUENTRA BAJO LA FORMA DE TABLETA O CAPSULA. DICHAS FORMAS DE DOSIS UNITARIA SON UTILES PARA EL TRATAMIENTO DE LA HIPERGLICEMIA, DISLIPIDEMIA, OBESIDAD, ANOREXIA NERVIOSA, ENTRE OTRAS
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US64790305P | 2005-01-28 | 2005-01-28 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20061041A1 true PE20061041A1 (es) | 2006-10-12 |
Family
ID=36616964
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2006000107A PE20061041A1 (es) | 2005-01-28 | 2006-01-24 | Formulaciones y regimen de dosificacion para moduladores alfa de ppar |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20080207716A1 (es) |
| EP (1) | EP1850845A2 (es) |
| JP (1) | JP2008528603A (es) |
| CN (1) | CN101106988A (es) |
| AR (1) | AR052888A1 (es) |
| BR (1) | BRPI0606805A2 (es) |
| CA (1) | CA2595770A1 (es) |
| DO (1) | DOP2006000018A (es) |
| MX (1) | MX2007009142A (es) |
| PE (1) | PE20061041A1 (es) |
| TW (1) | TW200640453A (es) |
| WO (1) | WO2006083645A2 (es) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2008248186B2 (en) | 2007-05-07 | 2014-02-06 | Merck Sharp & Dohme Corp. | Method of treatment using fused aromatic compounds having anti-diabetic activity |
| EP2612669A4 (en) | 2010-08-31 | 2014-05-14 | Snu R&Db Foundation | USING THE FÖTAL REPROGRAMMING OF A PPAR AGONIST |
| EP2822931B1 (en) | 2012-03-09 | 2017-05-03 | Inception 2, Inc. | Triazolone compounds and uses thereof |
| DK2935228T3 (en) | 2012-12-20 | 2017-10-30 | Inception 2 Inc | TRIAZOLONE COMPOUNDS AND APPLICATIONS THEREOF |
| EA201690230A1 (ru) | 2013-09-06 | 2016-07-29 | Инсепшн 2, Инк. | Соединения триазолона и их применения |
| WO2017044551A1 (en) * | 2015-09-11 | 2017-03-16 | Mitobridge, Inc. | Ppar-alpha agonists for treating mitochondrial diseases |
| WO2017181972A1 (zh) | 2016-04-22 | 2017-10-26 | 无锡杰西医药股份有限公司 | 异硫氰酸酯类化合物的应用 |
| WO2018016596A1 (ja) * | 2016-07-20 | 2018-01-25 | 国立大学法人東北大学 | ＰＰＡＲαアゴニストを含有する、肺高血圧症の予防又は治療剤 |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| UA82048C2 (uk) * | 2000-11-10 | 2008-03-11 | Эли Лилли Энд Компани | Агоністи альфа-рецепторів, активованих проліфератором пероксисом |
| SE0101981D0 (sv) * | 2001-06-01 | 2001-06-01 | Astrazeneca Ab | Pharmaceutical combination |
| DE60209824T2 (de) * | 2001-12-21 | 2006-10-19 | Smithkline Beecham Corp. | Dosierschema für ppar-gamma-aktivatoren |
-
2006
- 2006-01-24 DO DO2006000018A patent/DOP2006000018A/es unknown
- 2006-01-24 AR ARP060100266A patent/AR052888A1/es unknown
- 2006-01-24 PE PE2006000107A patent/PE20061041A1/es not_active Application Discontinuation
- 2006-01-24 TW TW095102645A patent/TW200640453A/zh unknown
- 2006-01-25 EP EP06719460A patent/EP1850845A2/en not_active Withdrawn
- 2006-01-25 WO PCT/US2006/002606 patent/WO2006083645A2/en not_active Ceased
- 2006-01-25 MX MX2007009142A patent/MX2007009142A/es not_active Application Discontinuation
- 2006-01-25 US US11/814,487 patent/US20080207716A1/en not_active Abandoned
- 2006-01-25 JP JP2007553198A patent/JP2008528603A/ja not_active Withdrawn
- 2006-01-25 BR BRPI0606805-7A patent/BRPI0606805A2/pt not_active IP Right Cessation
- 2006-01-25 CN CNA2006800031037A patent/CN101106988A/zh active Pending
- 2006-01-25 CA CA002595770A patent/CA2595770A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| WO2006083645A3 (en) | 2006-12-28 |
| AR052888A1 (es) | 2007-04-11 |
| EP1850845A2 (en) | 2007-11-07 |
| MX2007009142A (es) | 2007-11-21 |
| CN101106988A (zh) | 2008-01-16 |
| CA2595770A1 (en) | 2006-08-10 |
| BRPI0606805A2 (pt) | 2010-02-09 |
| WO2006083645A2 (en) | 2006-08-10 |
| TW200640453A (en) | 2006-12-01 |
| US20080207716A1 (en) | 2008-08-28 |
| JP2008528603A (ja) | 2008-07-31 |
| DOP2006000018A (es) | 2006-07-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2557303T3 (es) | Agente terapéutico para la estenosis del canal espinal | |
| ECSP099608A (es) | Preparacion solida que comprende alogliptina y pioglitazona | |
| PE20061041A1 (es) | Formulaciones y regimen de dosificacion para moduladores alfa de ppar | |
| AR054261A1 (es) | Sales fisiologicamente compatibles de ester etilico del acido 3-(2-{(4-(hexiloxicarbonilamino-imino-metil )-fenilamino]-metil}-1-metil-1h-bencimidazol-5-carbonil)-piridin-2-il-amino)-propionico, composiciones farmaceuticas que las contienen y su uso en la preparacion de un medicamento para la profil | |
| PE20100050A1 (es) | Forma de dosificacion farmaceutica para la liberacion inmediata de un derivado de indolinona | |
| AR059723A2 (es) | Composicion de altas dosis de ibandronato | |
| ES2648188T3 (es) | Composiciones y métodos para la modulación de amidasas específicas para N-aciletanolaminas para ser usadas en la terapia de enfermedades inflamatorias | |
| DOP2017000190A (es) | Formas de dosis de liberación controlada encerradas resistentes a manipulaciones indebidas | |
| AR094548A1 (es) | Dispersión sólida físicamente estable | |
| AR068919A1 (es) | 2-[3-(2,2-difluoro-benzo[1,3]dioxol-5-ilamino)-5-(2,6-dimetil-piridin-4-il)[1,2,4]triazol-1-il]-n-etil-acetamida y analogos del mismo, composiciones farmaceuticas que los contienen, proceso de preparacion y uso de los mismos en trastornos psicoticos y/o enfermedades con dificultades intelectuales. | |
| PE20170705A1 (es) | Nuevos compuestos como inhibidores de ret (reorganizado durante la transfeccion) | |
| PE20061150A1 (es) | Derivados de n-(n-sulfonilaminoarilmetil)ciclopropanocarboxamida sustituidos como antagonistas del receptor vainilloide tipo 1 (vdr1) | |
| AR065806A1 (es) | Derivados de quinolina, procesos para su preparacion, composiciones farmaceuticas que los contienen y usos para el tratamiento de la artritis reumatoidea. | |
| CU23808B7 (es) | Formas de presentación farmacéutica sólidas de administración oral con liberación rápida de principio activo | |
| PE20080056A1 (es) | Derivados de cromencarboxamida como antagonistas del receptor s1p1 | |
| EA201490014A1 (ru) | Модифицированное высвобождение 4-метил-3-[[4-(3-пиридинил)-2-пиримидинил]амино]-n-[5-(4-метил-1h-имидазол-1-ил)-3-(трифторметил)фенил]бензамида, солюбилизированного с использованием органических кислот | |
| CO6511280A2 (es) | Pastillas de gelatina blanda con nicotina | |
| CL2013000488A1 (es) | Co-cristales de compuestos derivados de (2r)-5-oxo-1-(bencilpiperidin-4-il)-n-(piridin-2-il)pirrolidin-2-carboxamida y un agente de formacion de co-cristales; sales de los compuestos; compuestos intermediarios; composicion farmaceutica; y su uso para el tratamiento de enfermedades inflamatorias e infecciosas. | |
| PE20191792A1 (es) | Derivados de isoxazol como agonistas del receptor nuclear y usos de los mismos | |
| AR065798A1 (es) | Usos terapeuticos de la 4-[2-(4-metilfenilsulfanil)fenil]piperidina | |
| PE20060362A1 (es) | Compuestos de oxazol como moduladores de ppar | |
| AR091621A1 (es) | Formas de presentacion farmaceuticas que contienen 5-cloro-n-({(5s)-2-oxo-3-[4-(3-oxo-4-morfolinil)-fenil]-1,3-oxazolidin-5-il}-metil)-2-tiofen-carboxamida | |
| RU2017112303A (ru) | Способ применения комбинации нового производного гидроксамовой кислоты и антибактериального вещества | |
| MX2017016862A (es) | Composicion farmaceutica estable para administracion oral. | |
| AR062925A1 (es) | Metodo para fabricar tabletas que contienen agentes farmacologicamente activos |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FC | Refusal |